ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Iowa » Hematology Oncology

Top Hematology Oncology Prescribers in Iowa

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JOSEPH MERCHANT M.D.

Hematology Oncology

4,436

$696K

369
333 are 65+

13%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 15%

$157
Average prescription price

Avg: $315

LARRY OTTEMAN MD

Hematology Oncology

3,525

$539K

314
280 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

8%
patients receiving schedule three controlled substances

Avg: 10%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 15%

$153
Average prescription price

Avg: $315

MARK GUFFY M.D.

Hematology Oncology

2,887

$405K

248
230 are 65+

8%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 15%

$140
Average prescription price

Avg: $315

THOMAS BUROKER DO

Hematology Oncology

2,548

$645K

307
277 are 65+

20%
patients receiving schedule two controlled substances

Avg: 13%

16%
patients receiving schedule three controlled substances

Avg: 10%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 15%

$253
Average prescription price

Avg: $315

ANOOP AGGARWAL M.D.

Hematology Oncology

2,517

$383K

278
248 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 15%

$152
Average prescription price

Avg: $315

MARK WESTBERG MD

Hematology Oncology

2,508

$1.02M

295
255 are 65+

15%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$407
Average prescription price

Avg: $315

DEBRA PROW M.D.

Hematology Oncology

2,303

$424K

279
246 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 15%

$184
Average prescription price

Avg: $315

CHIRANTAN GHOSH MD

Hematology Oncology

2,253

$876K

247
222 are 65+

13%
patients receiving schedule two controlled substances

Avg: 13%

15%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 15%

$389
Average prescription price

Avg: $315

BRADLEY HIATT DO

Hematology Oncology

2,232

$590K

298
250 are 65+

15%
patients receiving schedule two controlled substances

Avg: 13%

7%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$264
Average prescription price

Avg: $315

ROBERT SHRECK MD

Hematology Oncology

2,188

$972K

223
187 are 65+

19%
patients receiving schedule two controlled substances

Avg: 13%

17%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 15%

$444
Average prescription price

Avg: $315

DONALD WENDER M.D.

Hematology Oncology

1,987

$752K

357
307 are 65+

12%
patients receiving schedule two controlled substances

Avg: 13%

13%
patients receiving schedule three controlled substances

Avg: 10%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 15%

$378
Average prescription price

Avg: $315

RADHA RAO M.D.

Hematology Oncology

1,878

$503K

332
292 are 65+

9%
patients receiving schedule two controlled substances

Avg: 13%

13%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 15%

$268
Average prescription price

Avg: $315

SWALEH BAHAMADI MD

Hematology Oncology

1,862

$271K

216
195 are 65+

15%
patients receiving schedule two controlled substances

Avg: 13%

13%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 15%

$146
Average prescription price

Avg: $315

MATTHEW HILL DO

Hematology Oncology

1,686

$690K

215
169 are 65+

13%
patients receiving schedule two controlled substances

Avg: 13%

9%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$409
Average prescription price

Avg: $315

BORIANA KAMENOVA MD

Hematology Oncology

1,551

$1.05M

231
195 are 65+

9%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 15%

$676
Average prescription price

Avg: $315

STEPHEN KAHANIC MD

Hematology Oncology

1,429

$500K

261
231 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 15%

$350
Average prescription price

Avg: $315

JAMES FEELEY MD

Hematology Oncology

1,406

$463K

140
127 are 65+

11%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$329
Average prescription price

Avg: $315

DAVID MERCER MD

Hematology Oncology

1,390

$470K

177
136 are 65+

16%
patients receiving schedule two controlled substances

Avg: 13%

20%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 15%

$338
Average prescription price

Avg: $315

MOHAMMED MASRI MD

Hematology Oncology

1,338

$610K

159
133 are 65+

21%
patients receiving schedule two controlled substances

Avg: 13%

9%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 15%

$456
Average prescription price

Avg: $315

DEBRA WELKER MD

Hematology Oncology

1,314

$142K

165
148 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

7%
prescriptions for brand name drugs

Avg: 15%

$108
Average prescription price

Avg: $315

STEVEN HEDDINGER MD

Hematology Oncology

1,296

$439K

220
179 are 65+

12%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

10%
prescriptions for brand name drugs

Avg: 15%

$339
Average prescription price

Avg: $315

ANGELA SANDRE DO

Hematology Oncology

1,288

$640K

171
143 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

10%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 15%

$497
Average prescription price

Avg: $315

JOHN MICHALAK M.D.

Hematology Oncology

1,139

$191K

257
214 are 65+

10%
patients receiving schedule two controlled substances

Avg: 13%

12%
patients receiving schedule three controlled substances

Avg: 10%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 15%

$167
Average prescription price

Avg: $315

ROSCOE MORTON MD

Hematology Oncology

1,129

$380K

155
136 are 65+

14%
patients receiving schedule two controlled substances

Avg: 13%

0%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 15%

$336
Average prescription price

Avg: $315

ROBERT BEHRENS MD

Hematology Oncology

986

$465K

189
160 are 65+

20%
patients receiving schedule two controlled substances

Avg: 13%

9%
patients receiving schedule three controlled substances

Avg: 10%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 15%

$472
Average prescription price

Avg: $315

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank